Table 1.
The characteristics of PLWH and the serological data.
| Case 1 | Case 2 | Case 3 | Case 4a | Case 5a | |
|---|---|---|---|---|---|
| Age (years) | 35 | 31 | 27 | 51 | 32 |
| Sex | Male | Male | Male | TGW | TGW |
| CD4+ (cells/μL) | 321 | 380 | 235 | 835 | 501 |
| HIV-RNA (copies/mL) | Not Detected | Not Detected | Not Detected | Not Detected | Not Detected |
| ART | F/TAF + DTG | B/F/TAF | B/F/TAF | B/F/TAF | DTG/ABC/3TC |
| Symptoms | Fever, Cough, Change of taste | Change of taste | Fever, Sore throat | Fever | Fever, Cough |
| Severity | Mild | Mild | Mild | Mild | Mild |
| Infiltrates on radiograph | Bilateral pure GGO | None | Bilateral pure GGO | Bilateral pure GGO | Bilateral pure GGO |
| SARS-CoV2 viral load on admission | 1.0 × 106 (day 7) | No data (referral visit) | 7.0 × 108 (day 3) | 4.1 × 104 (day 4) | 22 (day 7) |
| Anti SARS-CoV2 IgM and IgG on admission | Negative | Negative | Negative | Negative | Negative |
| First positive of IgM (Titer, days)a | 0.19 (day 22) | Negative (day 87) | Negative (day 32) | Negative (day 15) | Negative (day 17) |
| First positive of IgG (Titer, days)b | 5.64 (day 22) | Negative (day 87) | 6.37 (day 32) | 7.6 (day 15) | 5.9 (day 17) |
| Anti COVID-19 therapy | Lopinavir/ritonavir | Favipiravir | Favipiravir | Lopinavir/ritonavir | none |
| Outcome | Cured | Cured | Cured | Cured | Cured |
Abbreviations; Transgender Women: TGW, Antiretroviral therapy: ART, Tenofovir alafenamide, emtricitabine and Bictegravir: B/F/TAF, Tenofovir alafenamide and emtricitabine: F/TAF, Dolutegravir: DTG, Dolutegravir sodium and Abacavir Sulfate and Lamivudine: DTG/ABC/3TC, Ground glass opacities: GGO.
a
Mokobio
b
Abbott.